<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Typography</title>
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.1.3/dist/c ss/bootstrap.min.css" rel="stylesheet">
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.1.3/dist/js /bootstrap.bundle.min.js"></script>
</head>
<body>
    <!DOCTYPE html>
<html>
<head>
<meta charset="utf-8">
<meta name="viewport" content="width=device-width">
<title>replit</title>
<link
href="https://cdn.jsdelivr.net/npm/bootstrap@5.1.3/dist/css/bootstrap.min.css"
rel="stylesheet">
<script
src="https://cdn.jsdelivr.net/npm/bootstrap@5.1.3/dist/js/bootstrap.bundle.min.j
s"></script>
</head>
<body>
<div class="bgimage">
<span class="badge rounded-pill bg-success">Latest News</span>
<div class="container border pt-5">
<h4 class="display-5"><span class="mark">Covid-19</span>: Molnupiravir
<small>benefits outweigh risks, say top medical experts</small></h4>
<p class="lead text-uppercase">Leading Covid-19 task force members and
health experts treating coronavirus patients across the country said on Monday
that the Covid antiviral drug <span class="mark">molnupiravir</span> is reducing
hospitalisation by 30-50 %, as well as the severity of the disease.</p>
</div>
<div class="container-fluid pt-5 bg-dark text-white">
<h4 class="display-5">What type of mask provides best protection from
<small>Omicron</small></h4>
2
<p class="lead text-lowercase">Everybody knows that face masks are key to
preventing the spread of the pandemic. But not all masks hold up well in the
face of the highly transmissible Omicron variant</p>
</div>
<div class="container pt-5 bg-primary ">
<h4 class="display-5">LIC IPO <small>Date, Price, Size, Valuation, <span
class="mark">LIC Policyholders'</span> Discount, All Latest Updates</small></h4>
<p class="lead text-capitalize">The much-awaited<span class="mark">
initial public offering (IPO)</span> of Life Insurance Corporation of India
(LIC) received in-principle approval from the board. However, the board has
reportedly asked for certain clarifications on the draft paper, according to
reports. The board is expected to meet again over the weekend to take the final
decision on LIC IPO draft prospectus. Once the board clear the draft document,
the centre will file it with the <span class="mark">market regulator</span>.</p>
<p class="lead ">LIC IPO draft red herring prospectus (DRHP) can be filed
with Securities and Exchange Board (Sebi) over the weekend or on February 15,
according to sources.</p>
<p class="lead">India is leaving <span class="mark">no stone
</span>unturned to make the biggest-ever listing a sucess. From tweaking capital
market rules to checking all the necessary details to avoid further delay, the
preparations for ‘mother of all IPOs’ are in full swing.</p>
<p class="lead">How Big will be <abbr title="Life Insurance
Corporation">LIC</abbr> <abbr title="Initial Public Offering">IPO</abbr>?</p>
<p class="lead">The embedded value of the <span class="mark">Life
Insurance Corporation</span> of India has been set at over Rs 5 lakh crore. The
valuation of LIC IPO is likely to be three to five times the embedded value. At
the current price, the LIC could command a valuation of over Rs 15 lakh crore
post listing according to experts.</p>
</div>
</div>
</body>
</html>
  
</body>
</html>